Bexarotene and DAB389IL-2 (Denileukin Diftitox, ONTAK) in Treatment of Cutaneous T-Cell Lymphomas: Algorithms

Clinical Lymphoma

Volumn 1, Issue 1 SUPPL., 2000, Pages

  Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bexarotene; DAB389IL 2; Denileukin diftitox; Mycosis fungoides; Retinoid X receptor

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; INTERLEUKIN 2; TETRALIN DERIVATIVE;

ALGORITHM; CUTANEOUS T CELL LYMPHOMA; DRUG COMBINATION; HUMAN; REVIEW; SKIN TUMOR;

ALGORITHMS; ANTICARCINOGENIC AGENTS; DIPHTHERIA TOXIN; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; INTERLEUKIN-2; LYMPHOMA, T-CELL, CUTANEOUS; RECOMBINANT FUSION PROTEINS; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 0002602825     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.s.010     Document Type: Article

References (19)

1. Bunn PA Jr., Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979; 63:725-728.
2. Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol 1999; 26:276-289.
3. Kaye FJ, Bunn PA Jr., Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321:1784-1790.
4. Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9:1031 -1056.
5. Heald P, Rook A, Perez M, et al.Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27:427-433.
6. Bunn PA Jr., Hoffman SJ, Morris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994; 121:592-602.
7. Duvic M, Cather JC. Emerging new therapies for cutaneous T-cell Iymphoma. Dermatol Clin 2000; 18:147-156.
8. 389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneousT cell lymphoma. Am J Hematol 1998; 58:87-90.
9. 389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998; 39:63-73.
10. Rizvi NA, Marshall JL, Dahut W, et al. A phase I study of LGD 1069 in adults with advanced cancer. Clin Cancer Res 1999; 5:1658-1664.
11. 486IL-2) in hématologie malignancies expressing the IL-2 receptor. Blood 1992; 79:2547-2554.
12. Thomsen K, Hammar H, Molin L, et al. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1989; 69:536-538.
13. Kuzel TM, Roenigk HH, Jr., Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 1995; 13:257-263.
14. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 34:1022-1029.
15. 389IL-2 (ONTAK) for the treatment of cutaneous T cell lymphoma. J Clin Oncol 2000; In Press.
16. Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood 1997; 89:32-40.
17. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35(4):573-579.
18. Posner LE, Fossieck BE, Jr., Eddy JL, et al. Septicemic complications of the cutaneous T-cell lymphomas. Am J Med 1981; 71:210-216.
19. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999; 340:1075-1079.